Congenital heart diseases (CHD) are the most frequent congenital diseases. GWAS and exome sequencing performed for the last decade revealed mutations in coding sequence in only a minority of CHD patients. Rather a high proportion of hits in epigenetic modifiers was found. Thus, the team physiopathology of cardiac development focuses its research on epigenetic regulation of cell fate determination during cardiac embryonic development. We are specifically focused on Tetralogy of Fallot and valve development and diseases, as they represent altogether 50% of cardiac congenital defects. These pathologies either lead to heart failure at the adulthood or become prominent in the aging population, respectively. Our research is also dedicated to better design strategies of cell therapy of heart failure for repaired tetralogy of Fallot, a complex cardiac congenital disease, for which reparation of the septal defect at birth has consequences on adult right ventricular function. To more specifically address such a broad biological question, we carry out different projects using patient specific iPS cell lines and mouse models of diseases:
The head of the team Michel Puceat is an INSERM director of research. He has signed more than 110 publications. He has acquired a background of cardiac biochemistry and physiology as well as cardiac developmental biology.